Analysts expect that Novavax, Inc. (NASDAQ:NVAX) will post $8.32 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Novavax’s earnings, with the highest sales estimate coming in at $10.30 million and the lowest estimate coming in at $6.00 million. Novavax reported sales of $5.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 54.1%. The firm is scheduled to announce its next quarterly earnings report on Monday, February 26th.
On average, analysts expect that Novavax will report full-year sales of $8.32 million for the current financial year, with estimates ranging from $26.76 million to $31.00 million. For the next fiscal year, analysts expect that the company will post sales of $35.24 million per share, with estimates ranging from $27.50 million to $42.50 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Novavax.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $8.35 million during the quarter, compared to the consensus estimate of $6.42 million. During the same period last year, the firm posted ($0.24) earnings per share. The company’s revenue for the quarter was up 158.5% on a year-over-year basis.
In other Novavax news, insider Stanley C. Erck acquired 100,000 shares of Novavax stock in a transaction dated Thursday, November 9th. The stock was purchased at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the acquisition, the insider now directly owns 228,279 shares of the company’s stock, valued at $257,955.27. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.00% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Novavax by 40.1% during the second quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company’s stock valued at $5,976,000 after buying an additional 1,488,403 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Novavax by 2.8% during the second quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company’s stock valued at $3,883,000 after buying an additional 92,854 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Novavax by 38.7% during the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock worth $1,944,000 after purchasing an additional 471,347 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Novavax by 14.5% during the second quarter. Bank of New York Mellon Corp now owns 1,391,610 shares of the biopharmaceutical company’s stock worth $1,600,000 after purchasing an additional 176,510 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Novavax by 6.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,225,018 shares of the biopharmaceutical company’s stock worth $1,397,000 after purchasing an additional 71,047 shares during the last quarter. Hedge funds and other institutional investors own 35.69% of the company’s stock.
Novavax (NVAX) traded down $0.37 on Friday, reaching $1.61. 31,501,010 shares of the company’s stock traded hands, compared to its average volume of 12,671,131. Novavax has a 12-month low of $0.73 and a 12-month high of $2.14. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28. The company has a market capitalization of $520.40, a P/E ratio of -2.37 and a beta of 2.03.
WARNING: “Analysts Anticipate Novavax, Inc. (NVAX) Will Announce Quarterly Sales of $8.32 Million” was first posted by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://weekherald.com/2018/01/21/analysts-anticipate-novavax-inc-nvax-will-announce-quarterly-sales-of-8-32-million.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.